Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
暂无分享，去创建一个
A. Luini | A. Goldhirsch | G. Viale | M. Intra | F. Bertolini | M. Colleoni | P. Veronesi | G. Perri | V. Bagnardi | E. Montagna | G. Cancello | C. Rampinelli | A. Calleri | S. Dellapasqua | D. Pastrello